Brown Brothers Harriman & Co’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.9M Sell
327,905
-16,584
-5% -$434K 0.03% 173
2026
Q1
$9.67M Buy
344,489
+134,886
+64% +$3.59M 0.05% 146
2025
Q4
$5.22M Buy
209,603
+20,355
+11% +$513K 0.03% 173
2025
Q3
$4.82M Buy
189,248
+3,875
+2% +$95.6K 0.03% 165
2025
Q2
$4.49M Buy
185,373
+23,812
+15% +$555K 0.03% 163
2025
Q1
$4.09M Sell
161,561
-15,512
-9% -$406K 0.03% 167
2024
Q4
$4.7M Sell
177,073
-33,854
-16% -$918K 0.03% 155
2024
Q3
$6.1M Buy
210,927
+6,232
+3% +$182K 0.04% 135
2024
Q2
$5.73M Sell
204,695
-5,911
-3% -$163K 0.04% 134
2024
Q1
$5.84M Buy
210,606
+5,736
+3% +$159K 0.04% 128
2023
Q4
$5.9M Sell
204,870
-28,334
-12% -$857K 0.05% 129
2023
Q3
$7.74M Buy
233,204
+4,666
+2% +$165K 0.07% 110
2023
Q2
$8.38M Sell
228,538
-1,036
-0.5% -$40.3K 0.07% 98
2023
Q1
$9.37M Buy
229,574
+463
+0.2% +$20K 0.08% 83
2022
Q4
$11.7M Sell
229,111
-30,250
-12% -$1.45M 0.1% 71
2022
Q3
$11.3M Sell
259,361
-11,849
-4% -$576K 0.11% 70
2022
Q2
$14.2M Buy
271,210
+7,406
+3% +$377K 0.12% 68
2022
Q1
$13.7M Sell
263,804
-5,170
-2% -$268K 0.1% 75
2021
Q4
$15.9M Buy
268,974
+13,043
+5% +$646K 0.09% 74
2021
Q3
$11M Sell
255,931
-17,743
-6% -$786K 0.07% 84
2021
Q2
$10.7M Sell
273,674
-4,589
-2% -$178K 0.06% 85
2021
Q1
$10.1M Sell
278,263
-59,825
-18% -$2.12M 0.06% 89
2020
Q4
$12.4M Sell
338,088
-8,140
-2% -$299K 0.08% 76
2020
Q3
$12.1M Sell
346,228
-1,915
-0.6% -$67.1K 0.09% 73
2020
Q2
$10.8M Buy
348,143
+8,930
+3% +$303K 0.08% 74
2020
Q1
$10.5M Sell
339,213
-30,869
-8% -$1.05M 0.09% 74
2019
Q4
$13.8M Buy
370,082
+7,582
+2% +$270K 0.09% 78
2019
Q3
$12.4M Buy
362,500
+49,359
+16% +$1.79M 0.08% 80
2019
Q2
$12.9M Buy
313,141
+14,405
+5% +$572K 0.09% 75
2019
Q1
$12M Sell
298,736
-4,594
-2% -$184K 0.08% 78
2018
Q4
$12.6M Sell
303,330
-1,250
-0.4% -$51.9K 0.1% 70
2018
Q3
$12.7M Buy
304,580
+251
+0.1% +$9.66K 0.08% 71
2018
Q2
$10.5M Sell
304,329
-1,897
-0.6% -$64.8K 0.06% 75
2018
Q1
$10.3M Sell
306,226
-17,483
-5% -$601K 0.06% 73
2017
Q4
$11.1M Sell
323,709
-10,312
-3% -$352K 0.06% 73
2017
Q3
$11.3M Sell
334,021
-11,363
-3% -$365K 0.06% 66
2017
Q2
$11M Sell
345,384
-16,065
-4% -$507K 0.06% 64
2017
Q1
$11.7M Sell
361,449
-14,999
-4% -$473K 0.06% 65
2016
Q4
$11.6M Buy
376,448
+4,908
+1% +$150K 0.06% 69
2016
Q3
$11.9M Sell
371,540
-2,478
-0.7% -$82.9K 0.06% 64
2016
Q2
$12.5M Sell
374,018
-18,569
-5% -$593K 0.06% 64
2016
Q1
$11M Sell
392,587
-206
-0.1% -$5.88K 0.06% 68
2015
Q4
$12M Sell
392,793
-17,136
-4% -$539K 0.06% 66
2015
Q3
$12.2M Sell
409,929
-18,029
-4% -$578K 0.06% 64
2015
Q2
$13.6M Sell
427,958
-12,807
-3% -$417K 0.06% 60
2015
Q1
$14.5M Buy
440,765
+7,918
+2% +$252K 0.07% 62
2014
Q4
$12.8M Sell
432,847
-6,852
-2% -$196K 0.05% 68
2014
Q3
$12.3M Sell
439,699
-21,546
-5% -$605K 0.05% 69
2014
Q2
$13M Sell
461,245
-13,136
-3% -$374K 0.05% 68
2014
Q1
$14.5M Sell
474,381
-510,363
-52% -$15.2M 0.06% 62
2013
Q4
$28.6M Buy
984,744
+498,289
+102% +$14.5M 0.06% 62
2013
Q3
$13.3M Sell
486,455
-62,282
-11% -$1.69M 0.06% 64
2013
Q2
$14.6M Buy
+548,737
New +$15.2M 0.07% 65

Other funds holding PFE

Brown Brothers Harriman & Co's PFE Position: Q2 2026 in Review

Brown Brothers Harriman & Co reduced its Pfizer (PFE) stake by 4.8% in Q2 2026, selling an estimated $434K and leaving 327,905 shares worth $7.9M. The position accounts for 0.03% of the portfolio, ranked #173.

Brown Brothers Harriman & Co first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $28.6M in Q4 2013. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Brown Brothers Harriman & Co held 327,905 shares of Pfizer worth $7.9M as of Q2 2026.
  • Brown Brothers Harriman & Co sold 16,584 Pfizer shares in Q2 2026, an estimated $434K.
  • Pfizer made up 0.03% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #173 holding.
  • Brown Brothers Harriman & Co first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Brown Brothers Harriman & Co's Pfizer position peaked at $28.6M in Q4 2013.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.